Umeå universitets logga

umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Precision medicine in complex diseases—Molecular subgrouping for improved prediction and treatment stratification
Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
NORMENT Centre, Division of Mental Health and Addiction, Oslo University Hospital & Institute of Clinical Medicine, University of Oslo, Oslo, Norway; KG Jebsen Centre for Neurodevelopment Research, University of Oslo, Oslo, Norway.
Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Rigshospitalet, Blegdamsvej 9, Copenhagen University Hospital, Copenhagen, Denmark.
Genetic and Molecular Epidemiology Unit, Lund University Diabetes Centre, Department of Clinical Science, Lund University, Lund, Sweden; Novo Nordisk Foundation, Hellerup, Denmark.
Visa övriga samt affilieringar
2023 (Engelska)Ingår i: Journal of Internal Medicine, ISSN 0954-6820, E-ISSN 1365-2796, Vol. 294, nr 4, s. 378-396Artikel, forskningsöversikt (Refereegranskat) Published
Abstract [en]

Complex diseases are caused by a combination of genetic, lifestyle, and environmental factors and comprise common noncommunicable diseases, including allergies, cardiovascular disease, and psychiatric and metabolic disorders. More than 25% of Europeans suffer from a complex disease, and together these diseases account for 70% of all deaths. The use of genomic, molecular, or imaging data to develop accurate diagnostic tools for treatment recommendations and preventive strategies, and for disease prognosis and prediction, is an important step toward precision medicine. However, for complex diseases, precision medicine is associated with several challenges. There is a significant heterogeneity between patients of a specific disease—both with regards to symptoms and underlying causal mechanisms—and the number of underlying genetic and nongenetic risk factors is often high. Here, we summarize precision medicine approaches for complex diseases and highlight the current breakthroughs as well as the challenges. We conclude that genomic-based precision medicine has been used mainly for patients with highly penetrant monogenic disease forms, such as cardiomyopathies. However, for most complex diseases—including psychiatric disorders and allergies—available polygenic risk scores are more probabilistic than deterministic and have not yet been validated for clinical utility. However, subclassifying patients of a specific disease into discrete homogenous subtypes based on molecular or phenotypic data is a promising strategy for improving diagnosis, prediction, treatment, prevention, and prognosis. The availability of high-throughput molecular technologies, together with large collections of health data and novel data-driven approaches, offers promise toward improved individual health through precision medicine.

Ort, förlag, år, upplaga, sidor
John Wiley & Sons, 2023. Vol. 294, nr 4, s. 378-396
Nyckelord [en]
complex diseases, genetic variations, genomic medicine, GWAS, molecular profiling, multi omics, polygenic risk score (PRS), precision medicine
Nationell ämneskategori
Medicinsk genetik
Identifikatorer
URN: urn:nbn:se:umu:diva-208069DOI: 10.1111/joim.13640ISI: 000974676300001PubMedID: 37093654Scopus ID: 2-s2.0-85153517541OAI: oai:DiVA.org:umu-208069DiVA, id: diva2:1760127
Forskningsfinansiär
Vetenskapsrådet, 2019-01497Vetenskapsrådet, 2016-0386Vetenskapsrådet, 2018-05619Hjärt-Lungfonden, 20200687Hjärt-Lungfonden, 20210546Hjärt-Lungfonden, 20210519Hjärt-Lungfonden, 20200693HjärnfondenCancerfonden, 22 2222 PjNovo Nordisk fonden, NF17OC002759Novo Nordisk fonden, NNF14CC001Novo Nordisk fonden, NF20OC005931Tillgänglig från: 2023-05-29 Skapad: 2023-05-29 Senast uppdaterad: 2024-03-26Bibliografiskt granskad

Open Access i DiVA

fulltext(869 kB)83 nedladdningar
Filinformation
Filnamn FULLTEXT02.pdfFilstorlek 869 kBChecksumma SHA-512
b056caa1f1a4ad40d39e651c37e6d4f93357f2ae654828cb4910fae0a30d66821548f998338055e8039e87537596806a088d89250982623941db57608814e0c2
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMedScopus

Person

Hedman, Harald

Sök vidare i DiVA

Av författaren/redaktören
Hedman, Harald
Av organisationen
Patologi
I samma tidskrift
Journal of Internal Medicine
Medicinsk genetik

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 198 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 617 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf